Vertex and Orna Join Forces to Revolutionize Blood Disorder Treatment
Summary:
Vertex Pharmaceuticals and Orna Therapeutics announce $700M partnership to develop innovative in-vivo gene editing therapies.
Vertex and Orna partner in a $700M deal to create groundbreaking in-body gene editing treatments, advancing beyond Casgevy to eliminate external cell modification for blood disorders.
Biogen Strengthens Leadership Team with New Head of Business Development
Summary:
Biogen appoints industry veteran Adam Feire as Head of Business Development and External Innovation, reinforcing its commitment to strategic growth.
Adam Feire joins Biogen from Novartis, bringing two decades of pharmaceutical expertise to lead business development and external partnerships for sustainable portfolio growth.
Barinthus Bio Pivots to Immunology Focus with Major Strategic Restructuring
Summary:
Barinthus Bio announces strategic shift to immunology and inflammation, cuts 65% workforce, and extends cash runway to 2027 while seeking partners for hepatitis B program.
Clinical-stage biotech Barinthus Bio restructures operations, prioritizing VTP-1000 for celiac disease while reducing UK presence. Phase 1 data expected mid-2025 with $112M cash runway to 2027
Gilead Sciences Forms $1.7B Alliance with LEO Pharma for Inflammatory Disease Programs
Summary:
Gilead Sciences partners with Denmark’s LEO Pharma in a $1.7B deal to develop STAT6 inhibitors for inflammatory conditions.
Gilead invests $250M upfront in LEO Pharma’s STAT6 program, gaining global rights for oral treatments in atopic dermatitis, asthma, and COPD, with potential royalties for LEO.
